These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2623384)

  • 1. Steady-state arterial and hepatic venous plasma concentrations of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine in animals--drugs which are subject to both splanchnic and extra-splanchnic elimination.
    Wagner JG; Stetson PL; Knol JA; Andrews JC; Walker-Andrews S; Knutsen CA; Johnson N; Prieskorn D; Terrio P; Yang Z
    Sel Cancer Ther; 1989; 5(4):193-203. PubMed ID: 2623384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.
    Kuan HY; Smith DE; Ensmiger WD; Knol JA; DeRemer SJ; Yang Z; Stetson PL
    Cancer Res; 1996 Oct; 56(20):4724-7. PubMed ID: 8840990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogs.
    Smith DE; Brenner DE; Knutsen CA; Deremer SJ; Terrio PA; Johnson NJ; Stetson PL; Ensminger WD
    Drug Metab Dispos; 1993; 21(2):277-83. PubMed ID: 8097697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical modulation of 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.
    Stetson PL; Normolle DP; Knol JA; Johnson NJ; Yang ZM; Sakmar E; Prieskorn D; Terrio P; Knutsen CA; Ensminger WD
    J Natl Cancer Inst; 1991 Nov; 83(22):1659-67. PubMed ID: 1836238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.
    Ensminger WD; Walker SC; Stetson PL; Wagner JG; Knol JA; Lawrence TS; Andrews JC
    Cancer Res; 1994 Apr; 54(8):2121-4. PubMed ID: 8174116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.
    Remick SC; Benson AB; Weese JL; Willson JK; Ramirez G; Wirtanen GW; Alberti DB; Nieting LM; Tutsch KD; Fischer PH
    Cancer Res; 1989 Nov; 49(22):6437-42. PubMed ID: 2804987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.
    Klecker RW; Jenkins JF; Kinsella TJ; Fine RL; Strong JM; Collins JM
    Clin Pharmacol Ther; 1985 Jul; 38(1):45-51. PubMed ID: 4006375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific pharmacodynamics of 5-bromo-2'-deoxyuridine incorporation into DNA in VX2 tumor-bearing rabbits.
    Stetson PL; Maybaum J; Wagner JG; Averill DR; Wollner IS; Knol JA; Johnson NJ; Yang ZM; Preiskorn D; Smith P
    Cancer Res; 1988 Dec; 48(23):6900-5. PubMed ID: 3180098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.
    Wagner JG; Gyves JW; Stetson PL; Walker-Andrews SC; Wollner IS; Cochran MK; Ensminger WD
    Cancer Res; 1986 Mar; 46(3):1499-506. PubMed ID: 3943107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.
    Lawrence TS; Davis MA; Maybaum J; Mukhopadhyay SK; Stetson PL; Normolle DP; McKeever PE; Ensminger WD
    Cancer Res; 1992 Jul; 52(13):3698-704. PubMed ID: 1617642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical applicability of current pharmacokinetic models: splanchnic elimination of 5-fluorouracil in cancer patients.
    Robinson PJ; Bass L; Pond SM; Roberts MS; Wagner JG
    J Pharmacokinet Biopharm; 1988 Jun; 16(3):229-49. PubMed ID: 3221324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial chemotherapy for primary and metastatic liver cancers.
    Ensminger W
    Cancer Chemother Pharmacol; 1989; 23 Suppl():S68-73. PubMed ID: 2647314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Bromo-2'-deoxyuridine incorporation into DNA in hepatic VX2 tumor-bearing rabbits.
    Knol JA; Stetson PL; Wagner JG; Johnson NJ; Yang ZM; Prieskorn D; Terrio P; Knutsen CA; Ensminger WD
    J Surg Res; 1989 Aug; 47(2):112-6. PubMed ID: 2755115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of 5-iodo-2'-deoxyuridine and 5-bromo-2'-deoxyuridine into rodent DNA as determined by neutron activation analysis.
    Kitchin KT; Brown JL
    Anal Biochem; 1995 Aug; 229(2):180-7. PubMed ID: 7485970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion.
    Knol JA; Walker SC; Robertson JM; Yang Z; DeRemer S; Stetson PL; Ensminger WD; Lawrence TS
    Cancer Res; 1995 Sep; 55(17):3687-91. PubMed ID: 7641176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells.
    Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
    Radiat Res; 1990 Aug; 123(2):192-8. PubMed ID: 2389005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.
    Russo A; Gianni L; Kinsella TJ; Klecker RW; Jenkins J; Rowland J; Glatstein E; Mitchell JB; Collins J; Myers C
    Cancer Res; 1984 Apr; 44(4):1702-5. PubMed ID: 6704976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells.
    Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
    Int J Radiat Oncol Biol Phys; 1992; 22(3):499-503. PubMed ID: 1735687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic galactose elimination kinetics in the intact pig.
    Keiding S; Johansen S; Winkler K
    Scand J Clin Lab Invest; 1982 May; 42(3):253-9. PubMed ID: 7134810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock.
    Reinelt H; Radermacher P; Kiefer P; Fischer G; Wachter U; Vogt J; Georgieff M
    Crit Care Med; 1999 Feb; 27(2):325-31. PubMed ID: 10075057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.